Moderna, Merck join forces to develop cancer vaccine

The following is an excerpt from Becker’s Hospital Review. Moderna and Merck entered an agreement Oct. 12 to develop, manufacture and sell personalized cancer vaccine candidates.  The two drugmakers have been collaborators since 2016, but under the amended agreement, Merck will pay Moderna $250 million before the end of 2022’s third quarter. They will equally share costs […]

Share DeepPol
Generated by Feedzy